

# Matrix RF™ Study



## Clinical Study to Evaluate the Performance of Fractional Radiofrequency for Improvement of Skin Texture via Skin Resurfacing and Wrinkle Reduction.

SKINQRI was one of only two centers in the US to participate in the FDA approval testing of the new Matrix RF™ system. Matrix RF™ is the first device to use ablative fractional bipolar radiofrequency energy for skin rejuvenation, wrinkle reduction, skin tightening and lifting. For the FDA approval testing, 47 people with moderate facial aging changes were enrolled at these two centers and received 3 facial treatments at one month intervals. Photographs were taken and the subjects were rated by the investigating physicians 1 month after the 2nd treatment and again 1 month after the 3rd treatment. The patient's satisfaction rating and perception of pain were also recorded.

Eighty five percent (85%) of patients in the study thought there was global improvement in their skin including tightening, reduction of wrinkles, and overall smoothness and brightness. On average 91% of patients rated the pain of the procedure and post procedure as zero to slight. Patients reported minimal downtime, usually described as 1-2 days of mild redness and 2-5 days of mild dryness. No adverse events were recorded.

Based on the results of this study, the Matrix RF™ is now FDA approved and Advanced

Dermatology is one of only two practices that have debuted it. We have been very pleased by the consistently good results, lack of downtime and discomfort and safety of the procedure and are optimistic about these early results.



Before treatment



1 month after 3rd treatment

